Insights

Acquisition Synergy Celator is a subsidiary of Jazz Pharmaceuticals, indicating potential cross-sell opportunities for Jazz’s hematology/oncology portfolio and Celator’s investigational pipeline in collaboration or integration discussions.

Late-Stage Potential With an investigation pipeline and Jazz’s proven oncology expertise, there may be opportunities to position Celator's assets in synergistic clinical development programs and early engagement with oncology-focused procurement teams.

Financial Leverage Revenue indicators and substantial funding suggest capacity for joint marketing, education initiatives, and payer-facing strategies to support new product launches or pipeline advancement.

Small-Mid Biotech Fit Company size (11-50 employees) indicates agility; target partnerships and contract manufacturing or CRO collaborations that fit a lean organization model and accelerate development timelines.

Market Positioning Industry focus on unmet medical needs and hematology/oncology alignment with Jazz may enable targeted outreach to specialty oncology centers, academic groups, and patient advocacy channels seeking innovative therapies.

Celator Pharmaceuticals Email Formats	Example	Percentage
FLast@celatorpharma.com	JDoe@celatorpharma.com	100%

Celator Pharmaceuticals Email Formats

Example

Percentage

FLast@celatorpharma.com

JDoe@celatorpharma.com

100%

Frequently Asked Questions

What is Celator Pharmaceuticals's phone number?

You can contact Celator Pharmaceuticals's main corporate office by phone at

+1-609-243-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Celator Pharmaceuticals's stock symbol?

Celator Pharmaceuticals is a publicly traded company; the company's stock symbol is CPXX.

What is Celator Pharmaceuticals's official website and social media links?

Celator Pharmaceuticals's official website is celatorpharma.com and has social profiles on LinkedIn.

How much revenue does Celator Pharmaceuticals generate?

As of July 2026, Celator Pharmaceuticals's annual revenue is estimated to be $1M - $10M.

What is Celator Pharmaceuticals's SIC code and NAICS code?

Celator Pharmaceuticals's SIC code is 8733 - Noncommercial Research Organizations and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Celator Pharmaceuticals have currently?

As of July 2026, Celator Pharmaceuticals has approximately 22 employees across 2 continents, including North America and Europe. Key team members include Research Associate: A. T., Aht, Arlat: C. B. and Human Resource Consultant, Owner: L. H. Explore Celator Pharmaceuticals's employee directory with LeadIQ.

What industry does Celator Pharmaceuticals belong to?

Celator Pharmaceuticals operates in the Biotechnology industry.

What is Celator Pharmaceuticals's email format?

Celator Pharmaceuticals's email format typically follows the pattern of FLast@celatorpharma.com. Find more Celator Pharmaceuticals email formats with LeadIQ.

How much funding has Celator Pharmaceuticals raised to date?

As of July 2026, Celator Pharmaceuticals has raised $176M in funding. The last funding round occurred on Mar 23, 2016.

When was Celator Pharmaceuticals founded?

Celator Pharmaceuticals was founded in 1999.

Celator Pharmaceuticals

Q: How many employees does Celator Pharmaceuticals have currently?

Celator Pharmaceuticals has approximately 22 employees.

Q: What is Celator Pharmaceuticals's NAICS code?

Celator Pharmaceuticals's NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

BiotechnologyNew Jersey, United States11-50 Employees

Celator Pharmaceuticals is a biotechnology research company based in Ewing, New Jersey, focused on advancing investigational therapies in collaboration with larger industry partners. It operates within the biotechnology research sector and has positioned itself as a contributor to hematology and oncology through its pipeline development. The organization emphasizes addressing unmet medical needs and improving patient outcomes by progressing new treatment options. As part of its recent corporate trajectory, Celator has become a subsidiary of Jazz Pharmaceuticals plc, reflecting a broader integration with a company that brings established expertise in hematology and oncology. This partnership suggests a continuity of Celator’s research initiatives within Jazz’s strategic focus while leveraging shared goals to advance these investigational therapies. The company’s location is noted as the Princeton-south Corporate Center in New Jersey, indicating its regional base of operations.

Insights

Similar companies to Celator Pharmaceuticals

Geron Corporation